Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis
US11819492B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 10, 2021 |
| Grant date | Nov 21, 2023 |
| Priority date | — |
| Expiry date | May 4, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D311/54
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a compound of the following general formula (I): or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.